Hepatitis c virus (HCV) is the major cause of chronic liver disease. Currently, it is estimated that around 170 million cases in the world are persistently infected with this virus, which remains a serious public health concern (
1). The treatment of hepatitis C is not effective in most cases, and is long and costly as well. Due to HCV genetic diversity and multiple mechanisms of persistence, there is still no approved vaccine for human use (
2,
3). Therefore, it is desirable to develop an efficient and low-cost vaccine to prevent or immunize people against HCV infection. It is shown that resolving HCV infection is associated with strong, sustained, and specific T cell response against multiple viral epitopes (
4).
Among HCV proteins, HCV core protein (HCVcp) contains several well-characterized CD4 and CD8 encoded epitopes and is one of the most conserved HCV antigens as well (
5). Applying core antigen in multi-component vaccines has been a successful strategy in animal and human clinical studies (
6-
8). Additionally, HCV core protein is employed in commercial HCV serological assays as a suitable capturing antigen to detect virus-specific antibodies and for diagnostic purposes (
9). However, since the C-terminal hydrophobic region of HCVcp exerts immunosuppressive effects (
2,
10), the N-terminal hydrophilic residue (HCVcp N-120), containing most of the conserved B and T cell epitopes, was employed for different diagnostic (
9,
11) and vaccine applications (
12-
14).
Therefore, to satisfy different diagnostic, research, and therapeutic demands, the production of HCVcp in various expression systems is addressed (
2,
15,
16). Transgenic plants as environmentally friendly alternatives to conventional expression systems offer the possibility to produce an immunogen on an agricultural-scale with low production costs, lack of human pathogen and endotoxins (
17,
18). Currently several plant-derived viral proteins such as hepatitis B surface antigen (
19) and Norwalk virus capsid protein (
20) are in clinical trial vaccine studies.
Recently, establishing transgenic tobacco plants expressing HCVcp (
21) or directing the expression of the first 143 amino acids from N-terminal in tobacco chloroplasts (
22) are reported. However, in leafy crops such as tobacco, recombinant proteins are synthesized in an aqueous environment in which they are often unstable. In addition, other properties such as low protein content, high protease activity and the presence of phenolic compounds could negatively affect yield gains and storage stability of the harvested biomass (
23). In this regard, plant seed is an attractive organ to produce and store recombinant protein. Indeed, the accumulation of recombinant proteins in seeds is reported at high levels in various studies (
24,
25). As an example, the
Escherichia coli heat-labile toxin B subunit (LT-B) accumulated to 2.4% of the total seed protein in soybean seed by glycinin seed promoter (
26), which was much higher than those of tobacco up to 0.01% Total Soluble Protein (TSP) (
27), and lettuce up to 0.05% TSP (
28); using the LTB gene under the control of the CaMV 35S strong promoter. It is also shown that recombinant proteins in seeds remain stable and functional for years at ambient temperature (
29,
30).
During the last two decades, varieties of seed-based production platforms were developed in different plants, including cereals, legumes, and oilseeds (
25). Canola (
Brassica napus L.) seed has a great potential as a platform to produce and deliver antigenic proteins. In addition to the plant extensive and worldwide distribution, the seed offers high protein content, more than 20%, compared to 1% - 2% in leaf tissues (e g, tobacco) resulting in accumulation of recombinant proteins in a compact biomass (
31). Moreover, canola oilseed was a source of separate entities of small (0.6 - 2 μm diameter) storage oil droplets termed oil-bodies. As an advantage, the oil-bodies in vaccine applications can serve as an attractive carrier to present and deliver foreign antigenic proteins (
32).
In the previous studies, the seed specific promoter fatty acid elongase 1 (FAE1) was isolated and efficiently applied to down regulate the erucic acid production in transgenic rapeseed by antisense construct of the FAE gene (
33). Also, in a recent study, the expression controlled by the FAE seed-specific promoter was successful in producing the fusion espA, intimin and tir (EIT) antigen of enterohemorrhagic
Escherichia coli (EHEC) in transgenic canola (
31). To increase the expression level, in addition to using specific expression in high protein and low hydrolyzing enzyme organelle such as seed, two other strategies were applied; an increase of the transcript level by optimizing the synthetic sequence for plant host was conducted, and targeting the protein to the endoplasmic reticulum (ER) subcellular organelle by KDEL (Lys-Asp-Glu-Leu) retention signal was included.